
Home » GENELABS ANNOUNCES FORECAST OF MID-YEAR CASH LEVEL AND NOTIFICATION FROM NASDAQ
GENELABS ANNOUNCES FORECAST OF MID-YEAR CASH LEVEL AND NOTIFICATION FROM NASDAQ
Genelabs Technologies, Inc. announced today that, after its receipt of $12.5 million in up-front payments under its recently announced agreement with Novartis, Genelabs expects its June 30, 2006 cash and cash equivalents to be approximately $15 million. The mid-year cash level anticipated by the company accounts for costs related to closing the transaction and anticipated second quarter operating expenses. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-09-2006/0004377619&EDATE=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Oct
-
16Oct
-
26Oct
-
02Nov
-
08Nov